TCI > Innovations > Scientific Publications > Bacillus coagulans TCI711 Supplementation Improved Nonalcoholic Fatty Liver by Modulating Gut Microbiota: A Randomized, Placebo-Controlled, Clinical Trial
Bacillus coagulans TCI711 Supplementation Improved Nonalcoholic Fatty Liver by Modulating Gut Microbiota: A Randomized, Placebo-Controlled, Clinical Trial
Scientific Publications

Bacillus coagulans TCI711 Supplementation Improved Nonalcoholic Fatty Liver by Modulating Gut Microbiota: A Randomized, Placebo-Controlled, Clinical Trial

Paper Title

Bacillus coagulans TCI711 Supplementation Improved Nonalcoholic Fatty Liver by Modulating Gut Microbiota: A Randomized, Placebo-Controlled, Clinical Trial

IngredientTCI711 Bacillus coagulans
BenefitLiver Health
Study TypeClinical Trial
JournalCurrent Developments in Nutrition. 2024; 8: 102083
DOI: 10.1016/j.cdnut.2024.102083

* This page summarizes a study published by TCI in a peer-reviewed journal. Please refer to the original journal for full details.